Mawer Investment Management Ltd. Increases Stake in Medpace Holdings, Inc. $MEDP

Mawer Investment Management Ltd. boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.4% during the 2nd quarter, Holdings Channel reports. The firm owned 817,432 shares of the company’s stock after acquiring an additional 121,213 shares during the quarter. Medpace comprises approximately 1.3% of Mawer Investment Management Ltd.’s investment portfolio, making the stock its 21st largest position. Mawer Investment Management Ltd.’s holdings in Medpace were worth $256,559,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in MEDP. Allworth Financial LP grew its holdings in shares of Medpace by 9,708.8% during the second quarter. Allworth Financial LP now owns 5,591 shares of the company’s stock valued at $1,755,000 after buying an additional 5,534 shares during the last quarter. Joseph Group Capital Management raised its stake in shares of Medpace by 27.4% in the second quarter. Joseph Group Capital Management now owns 5,317 shares of the company’s stock worth $1,669,000 after purchasing an additional 1,144 shares during the last quarter. King Luther Capital Management Corp lifted its holdings in shares of Medpace by 1.5% during the second quarter. King Luther Capital Management Corp now owns 20,861 shares of the company’s stock worth $6,547,000 after purchasing an additional 311 shares during the period. Roberts Glore & Co. Inc. IL boosted its position in Medpace by 3.3% in the second quarter. Roberts Glore & Co. Inc. IL now owns 4,391 shares of the company’s stock valued at $1,378,000 after buying an additional 140 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Medpace in the 2nd quarter worth approximately $1,059,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.9%

Shares of MEDP opened at $600.44 on Tuesday. The firm has a market cap of $16.91 billion, a P/E ratio of 41.99, a PEG ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00. The stock’s 50 day moving average is $530.23 and its two-hundred day moving average is $416.22.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the firm posted $3.01 EPS. The business’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Mizuho lifted their price objective on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. TD Cowen upped their price target on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $475.90.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the transaction, the chief executive officer directly owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $8,934,900. The trade was a 58.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 116,211 shares of company stock valued at $63,569,958. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.